Pipeline

Program Therapeutic Area/Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Post Market Commercial Rights
Internal Programs
Etrasimod
Optimized Activity S1P Receptor Modulator
Ulcerative Colitis (UC) 1

73%

Ulcerative Colitis (UC) 2

73%

Crohn’s Disease (CD)

73%

Atopic Dermatitis (AD)

45%

Arena: Worldwide, excluding rights granted to Everest Medicines for Greater China & certain other Asian territories
Olorinab
Highly Selective Full Agonist CB2
Pain Associated with IBD

60%

Pain Associated with IBS

45%

Arena: Worldwide
APD418 Calcium-Independent Myofilament Derepressor
Decompensated heart failure (DHF)

17%

Arena: Worldwide
Partnered / Licensed Programs
Ralinepag (Potent IP Receptor Agonist)
Pulmonary Arterial Hypertension (PAH)

75%

United Therapeutics
BELVIQ and BELVIQ XR
Weight Loss Approved: CVOT Completed

98%

Eisai: Worldwide
Undisclosed Orphan GPCR
CNS

15%

Boehringer Ingelheim
Undisclosed Novel GPCR
Genitourinary Disorders

15%

Outpost Medicine
Program Therapeutic Area/Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Post Market Commercial Rights

Program Indication Phase
Internal Programs
Etrasimod
Optimized Activity S1P Receptor Modulator
Ulcerative Colitis (UC) 1 Ph3 Planning
Ulcerative Colitis (UC) 2 Ph3 Planning
Crohn’s Disease (CD) Ph2/3 Planning
Atopic Dermatitis (AD) Ph2 Planning
Olorinab
Highly Selective Full Agonist CB2
Pain Associated with IBD Ph2 Data
Pain Associated with IBS Ph2 Planning
APD418
Calcium-Independent Myofilament Derepressor
Decompensated heart failure (DHF) IND 2019
Partnered / Licensed Programs
Ralinepag (Potent IP Receptor Agonist)
Pulmonary Arterial Hypertension (PAH) Ph3
BELVIQ and BELVIQ XR
Weight Loss Approved: CVOT Completed Post Market
Undisclosed Orphan GPCR
CNS PC
Undisclosed Novel GPCR
Genitourinary Disorders PC

Expanded Access Policy